PMID- 36653007
OWN - NLM
STAT- MEDLINE
DCOM- 20230120
LR  - 20230120
IS  - 1003-0034 (Print)
IS  - 1003-0034 (Linking)
VI  - 36
IP  - 1
DP  - 2023 Jan 25
TI  - [Analysis of the effect of midazolam on pain in a rat model of lumbar disc 
      herniation based on the p38 MAPK signaling pathway].
PG  - 55-60
LID - 10.12200/j.issn.1003-0034.2023.01.010 [doi]
AB  - OBJECTIVE: To investigate the effect of midazolam on pain in lumbar disc 
      herniation model rats based on p38 MAPK signaling pathway. METHODS: Fifty 
      SPF-grade Sprague-Dawley healthy rats, half male and half female, were selected 
      and randomly divided into normal group, model group, and low-dose, medium-dose, 
      high-dose groups. Model group and low-dose, medium-dose, high-dose groups were 
      initially modeled for lumbar disc herniation. Intraperitoneal injection of saline 
      was performed in rats of normal and model groups; and in the low-dose, 
      medium-dose, and high-dose groups, intraperitoneal injection of midazolam was 
      performed with doses of 30, 60, and 90 mg/kg, respectively. Interleukin-1beta 
      (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), 5-hydroxytryptamine (5-HT), beta-endorphin 
      (beta-EP), substance P (SP), neuropeptide Y (NPY) were detected in the serum of rats 
      by enzyme-linked immunoassay. The expression of p38 MAPK and matrix 
      metalloproteinase-3(MMP-3) protein were detected by Western blot in the tissues 
      of rats of each group. RESULTS: The levels of TNF-alpha, IL-1beta and beta-EP were higher 
      and the level of 5-HT was lower in the model group than in the normal 
      group(P<0.05);the levels of TNF-alpha, IL-1beta and beta-EP were lower and the level of 
      5-HT was higher in the low-dose, medium-dose and high-dose groups than in the 
      model group(P<0.05). The levels of SP and NPY increased in the model group 
      compared with the normal group (P<0.05) and the levels of SP and NPY decreased in 
      the low-dose, medium-dose and high-dose groups compared with the model group 
      (P<0.05). The expression of p38 MAPK and MMP-3 increased in the model group 
      compared with the normal group (P<0.05); the expression of p38 MAPK and MMP-3 
      decreased in the low-dose, medium-dose and high-dose compared with the model 
      group(P<0.05). CONCLUSION: Midazolam may ameliorate the immune inflammatory 
      response in rats with a model of lumbar disc herniation, possibly regulated 
      through the p38MAPK signaling pathway.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of Anesthesiology, Kailuan General Hospital Zhaogezhuang Hospital, 
      Guzhi 063101, Hebei, China.
FAU - Ye, Yu-Jun
AU  - Ye YJ
AD  - Department of Anesthesiology, Tangshan Hospital of Traditional Chinese Medicine, 
      Tangshan 063000, Hebei, China.
FAU - Liu, Shu-Min
AU  - Liu SM
AD  - Department of Anesthesiology, Kailuan General Hospital Zhaogezhuang Hospital, 
      Guzhi 063101, Hebei, China.
FAU - Liu, Shuang
AU  - Liu S
AD  - Department of Surgery, Kailuan General Hospital Zhaogezhuang Hospital, Guzhi 
      063101, Hebei, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Gu Shang
JT  - Zhongguo gu shang = China journal of orthopaedics and traumatology
JID - 9815790
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - R60L0SM5BC (Midazolam)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 333DO1RDJY (Serotonin)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Rats
MH  - Male
MH  - Female
MH  - Animals
MH  - *Intervertebral Disc Displacement/drug therapy/pathology
MH  - Rats, Sprague-Dawley
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Midazolam
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Serotonin/metabolism
MH  - MAP Kinase Signaling System/physiology
MH  - Pain
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Immunity
OT  - Inflammation
OT  - Intervertebral disk displacement
OT  - Lumbar vertebrae
OT  - Pain
OT  - p38MAPK signaling pathway
EDAT- 2023/01/19 06:00
MHDA- 2023/01/21 06:00
CRDT- 2023/01/18 19:52
PHST- 2023/01/18 19:52 [entrez]
PHST- 2023/01/19 06:00 [pubmed]
PHST- 2023/01/21 06:00 [medline]
AID - 10.12200/j.issn.1003-0034.2023.01.010 [doi]
PST - ppublish
SO  - Zhongguo Gu Shang. 2023 Jan 25;36(1):55-60. doi: 
      10.12200/j.issn.1003-0034.2023.01.010.